Dr. Funda Meric-Bernstam, MD
Claim this profileM D Anderson Cancer Center
About Funda Meric-Bernstam, MD
Education:
- Earned an MD from Yale University in 1991.
Experience:
- Serves as an Associate Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center.
- Specializes in translational research on breast cancer, with a focus on gene expression alterations and the mTOR signaling pathway.
- Utilizes a range of molecular biology techniques in her research.
- Took a two-year research hiatus at the NIH during her general surgery residency.
- Awarded the Society of University Surgeons (SUS) Resident Research Award for her contributions to surgical research.
Area of expertise
Solid Tumors
Funda Meric-Bernstam, MD has run 19 trials for Solid Tumors. Some of their research focus areas include:
Cancer
Funda Meric-Bernstam, MD has run 18 trials for Cancer. Some of their research focus areas include:
Affiliated Hospitals
M D Anderson Cancer Center
The University Of Texas M.D. Anderson Cancer Center
Clinical Trials Funda Meric-Bernstam, MD is currently running
ACR-368
for Ovarian Cancer
This trial tests a new drug, ACR-368, alone or with a small dose of another drug, gemcitabine, in patients whose cancers don't respond to standard treatments. A special test helps decide which treatment might work best for each patient. Gemcitabine has been used with other drugs for various cancers, including pancreatic, lung, ovarian, and breast cancers.
Recruiting
1 award
Phase 2
10 criteria
Zotatifin
for Solid Tumors
This trial is testing a new drug called Zotatifin for patients with advanced cancers that haven't improved with standard treatments. The drug works by stopping cancer cells from making essential proteins, which may slow or stop the cancer.
Recruiting
3 awards
Phase 1 & 2
21 criteria
More about Funda Meric-Bernstam, MD
Clinical Trial Related
16 years of experience running clinical trials · Led 37 trials as a Principal Investigator · 16 Active Clinical Trials
Treatments Funda Meric-Bernstam, MD has experience with
- Binimetinib
- Paclitaxel
- Palbociclib
- Pembrolizumab
- Ipatasertib
- Trastuzumab Deruxtecan
Breakdown of trials Funda Meric-Bernstam, MD has run
Solid Tumors
Cancer
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Funda Meric-Bernstam, MD specialize in?
Funda Meric-Bernstam, MD focuses on Solid Tumors and Cancer. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are Stage III.
Is Funda Meric-Bernstam, MD currently recruiting for clinical trials?
Yes, Funda Meric-Bernstam, MD is currently recruiting for 16 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Funda Meric-Bernstam, MD has studied deeply?
Yes, Funda Meric-Bernstam, MD has studied treatments such as Binimetinib, Paclitaxel, Palbociclib.
What is the best way to schedule an appointment with Funda Meric-Bernstam, MD?
Apply for one of the trials that Funda Meric-Bernstam, MD is conducting.
What is the office address of Funda Meric-Bernstam, MD?
The office of Funda Meric-Bernstam, MD is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.